Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,696 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia Praecox Clear all
Completed Not applicable Interventional Results available

Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia

NCT01551979
View directory record Official record
Conditions
Schizophrenia
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jul 24, 2026, 3:04 PM EDT
Not yet recruiting Phase 3 Interventional

52-week Open Label Safety-Tolerability Study

NCT07369154
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
23
States / cities
Chandler, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jul 24, 2026, 3:04 PM EDT
Recruiting Not applicable Interventional

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

NCT05656469
View directory record Official record
Conditions
Mood Disorders, Anxiety Disorders, Psychotic Disorders
Interventions
Personalised medication advice based on pharmacogenetic testing
Other
Lead sponsor
Parnassia Groep
Other
Eligibility
16 Years to 70 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

NCT03360695
View directory record Official record
Conditions
Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer
Interventions
Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Jul 24, 2026, 3:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

NCT02614586
View directory record Official record
Conditions
Schizophrenia
Interventions
TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Mobile Technology to Enhance Early Psychosis Treatment Delivery

NCT03303456
View directory record Official record
Conditions
Psychosis, Clinical High Risk for Psychosis
Interventions
Mobile health application - Ginger.io
Other
Lead sponsor
University of California, Davis
Other
Eligibility
13 Years to 30 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Tryptophan MRI in People With Schizophrenia and Healthy Controls

NCT02067975
View directory record Official record
Conditions
Schizophrenia
Interventions
Tryptophan, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 24, 2026, 3:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Targeting Individual Alpha Frequencies to Enhance Perceptual Timing

NCT04856657
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder
Interventions
Transcranial alternating current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 24, 2026, 3:04 PM EDT
Terminated Not applicable Interventional Results available

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

NCT00794963
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
19 Years to 79 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 2 Interventional Results available

Fingolimod in Schizophrenia Patients

NCT01779700
View directory record Official record
Conditions
Schizophrenia
Interventions
Fingolimod, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 24, 2026, 3:04 PM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCT03351244
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

NCT00650611
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
17
States / cities
San Diego, California • Altamonte Springs, Florida • Libertyville, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tolerability of MDMA in Schizophrenia

NCT05770375
View directory record Official record
Conditions
Schizophrenia
Interventions
MDMA 40mg, MDMA 80mg, MDMA 120mg
Drug
Lead sponsor
Anya Bershad, MD, PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Jul 24, 2026, 3:04 PM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Peer Approaches to Substances in Early Psychosis Programs: A Pilot Study of a Peer-Led Intervention

NCT04517279
View directory record Official record
Conditions
Psychotic Disorders, Substance Use
Interventions
Peer Approach to Substances in Early Psychosis Programs, Usual Care Peer Services
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
15 Years to 32 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Austin, Texas • Beaumont, Texas • Big Spring, Texas + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 24, 2026, 3:04 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

NCT07061288
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

NCT07043803
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
Interventions
Reduction of anticholinergic medication
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Altoona, Pennsylvania • Erie, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 2 Interventional

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCT00265551
View directory record Official record
Conditions
Schizophrenia
Interventions
SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness

NCT00661869
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Wellness Program
Other
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Jul 24, 2026, 3:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia

NCT00356317
View directory record Official record
Conditions
Schizophrenia
Interventions
Culturally informed therapy for schizophrenia (CIT-S), Psychoeducation treatment as usual
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Jul 24, 2026, 3:04 PM EDT